Saxenda vs Retatrutide
Editorial comparison of Saxenda (liraglutide) and Retatrutide (retatrutide). Same drug class context, trial-anchored data, no marketing claims.
Side-by-side
| Dimension | Saxenda | Retatrutide |
|---|---|---|
| Generic name | liraglutide | retatrutide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approved | 2014 | — |
| Mechanism | Single GLP-1 receptor agonist. Same mechanism family as semaglutide/Wegovy but shorter half-life (~13 hours) requiring daily dosing instead of weekly. | Where semaglutide hits one receptor and tirzepatide two, retatrutide adds a third: the glucagon receptor. |
| Dosing | Titrated weekly: 0.6mg → 1.2mg → 1.8mg → 2.4mg → 3.0mg maintenance, all once daily. | Investigational. Trial dosing is once-weekly subcutaneous injection with gradual titration; final approved doses are not set. |
| Cost | List price ~$1,350/month. Cash-pay similar. Insurance coverage variable. Cheaper coupons through Novo Nordisk savings card programs. | No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product. |
| Pivotal trial result | 8.4% mean body-weight reduction at 56 weeks (3.0 mg dose) | ~24% mean body-weight reduction at 48 weeks (highest dose, Phase 2) |
Full Saxenda review →
FDA-approved daily injectable liraglutide for chronic weight management. Older-generation GLP-1, daily dosing.
Full Retatrutide review →
Investigational triple agonist (GLP-1 / GIP / glucagon). Phase 3 weight loss approached ~24%, the highest yet. Not FDA-approved; expected 2027.
Frequently asked
Is Saxenda or Retatrutide more effective?+
In their pivotal trials, Saxenda reported 8.4% mean body-weight reduction at 56 weeks (3.0 mg dose), while Retatrutide reported ~24% mean body-weight reduction at 48 weeks (highest dose, Phase 2). Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.
How do Saxenda and Retatrutide compare on cost?+
Saxenda: List price ~$1,350/month. Cash-pay similar. Insurance coverage variable. Cheaper coupons through Novo Nordisk savings card programs. Retatrutide: No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.
Can I switch from Saxenda to Retatrutide?+
Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.
Are Saxenda and Retatrutide the same drug?+
No. Saxenda (liraglutide) and Retatrutide (retatrutide) are distinct medications from Novo Nordisk and Eli Lilly respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.